Patrick He

Patrick He

Auto-generated profile, based on publicly available information

Patrick He

Respiratory Technology, Woolcock Institute of Medical Research, Macquarie University, Sydney, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Pharmacological Reports
Verified
Journal Article
Closed access
PHPatrick He
Patrick He
ASAaron Smith
Aaron Smith
IGIngrid C. Gelissen
Ingrid C. Gelissen
AAAlaina J. Ammit
Alaina J. Ammit

16 October 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
PHPatrick He
Patrick He
ISImco Sibum
Imco Sibum
WNWietze Nijdam
Wietze Nijdam
NBNicolas Buchmann
Nicolas Buchmann
JSJulio Soria
Julio Soria
DTDaniela Traini
Daniela Traini

25 February 2026 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
PHPatrick He
Patrick He
HGHanieh Gholizadeh
Hanieh Gholizadeh
DCDamien Chong
Damien Chong
SCShaokoon Cheng
Shaokoon Cheng
PSPatrick Spicer
Patrick Spicer
HOHui Xin Ong
Hui Xin Ong
Purpose: The Advanced Integrated Respiratory (AIR) model was developed as a physiologically relevant benchtop system designed to assess aerosol deposition and interactions within the respiratory tract. Methods: This model integrates a three-dimensional (3D) cast of the human airways with a vacuum driven aerosol inhalation flow and an air liquid interface (ALI) cell culture platform. In this study, the integrated AIR and ALI cell model was used to investigate the toxicity profile of aerosolized Ricinus communis agglutinin-1 (RCA I) toxin. RCA I was characterized in terms of particle size, surface charge, rheology, and aerosol performance. Additionally, real-time electrochemical detection using the Micro Analytical Device (MAD) provided high sensitivity quantification of aerosolized RCA I. The biological effects were assessed using human epithelial cells cultured under ALI conditions, which were exposed to RCA I aerosols. Cytotoxicity and barrier function assays were performed to evaluate its impact. Results: Results show significant differences in toxic dose thresholds comparing 2D and AIR models. Transport study revealed that RCA I exhibited significantly increased mass transport across the epithelial cell layer at toxic concentrations compared to non-toxic concentrations. Conclusions: This integrated approach represents a significant advancement in the study of inhaled aerosol deposition, toxicity, and pharmacokinetics, offering a robust tool for predicting lung injury and enhancing the detection of a wide range of inhaled aerosols, including but not limited to toxins.

20 February 2026 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
PHPatrick He
Patrick He
HLHazel Lam
Hazel Lam
DCDamien Chong
Damien Chong
SCShaokoon Cheng
Shaokoon Cheng
PSPatrick Spicer
Patrick Spicer
HOHui Xin Ong
Hui Xin Ong
Purpose: In vitro respiratory models such as the Next Generation Impactor (NGI), remain the gold standard for aerodynamic particle size distribution (APSD) testing, however, they lack the anatomical complexity, limiting their ability to replicate in vivo deposition. To address this limitation, the Advanced Integrated Respiratory (AIR) model, a physiologically relevant benchtop system incorporating anatomically accurate silicone casts of the upper and lower airways, was used to assess deposition of salbutamol sulphate delivered via three clinically relevant platforms. Methods: Salbutamol sulphate was delivered using a pressurised metered-dose inhaler (pMDI), a dry powder inhaler (DPI), and a jet nebuliser. Deposition profiles obtained in the AIR model were benchmarked against the NGI. Results: Both systems showed consistent patterns for DPI and nebuliser aerosols, with highest deposition in the oropharyngeal and intrathoracic regions, respectively. In contrast, pMDI testing revealed important differences: the AIR model predicted markedly higher oropharyngeal retention and reduced intrathoracic delivery, aligning more closely with published in vivo scintigraphy studies than the NGI. Conclusion: These findings demonstrate that anatomically realistic models provide critical insights into deposition behaviour, particularly for propellant driven inhalers and underscore the value of integrating physiologically relevant platforms alongside conventional impactors in aerosol characterisation.

14 April 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
DDDaniel J. Duke
Daniel J. Duke
HWHaiqiao Wang
Haiqiao Wang
LRLingzhe Rao
Lingzhe Rao
EMEthan McRae
Ethan McRae
PHPatrick He
Patrick He
PYPaul Young
Paul Young
Design of the mouthpiece of a pressurised metered dose inhaler is generally informed by patient needs, followed by manufacturing and product differentiation considerations. However, relatively few studies have investigated whether the size and shape of the mouthpiece might be altered to adjust drug deposition. The motivation for such adjustment is the impending switch to low-global warming potential (GWP) propellants with differing plume geometry and deposition characteristics. In this study we investigate how the size and shape of the mouthpiece affects aerodynamic particle size distribution and spray plume geometry for a model solution formulation of 2 mg/mL beclomethasone dipropionate in 8% w/w ethanol. Six mouthpiece designs were investigated for a control formulation with HFA-134a propellant. A partial parametric study was also conducted for formulations in HFA-152a and HFO-1234ze(E) propellants. The mouthpiece shape had a statistically significant effect on mouthpiece and throat deposition as expected, but with no statistically significant change at smaller particle sizes, since aerosol maturation is primarily influenced by formulation and actuator orifice design. Significance was reduced for low-GWP propellants using the larger mouthpiece designs. Analysis of ex-mouthpiece plume geometry revealed that the mouthpiece shape and size had no significant effect on the ensemble-average plume geometry, but did have an effect on the degree of shot-to-shot variation between actuations. These results show that mouthpiece design may be a useful means of adjusting the balance between throat and mouthpiece deposition without altering APSD at the respirable size range when formulating low-GWP pMDIs to achieve equivalent APSD outcomes to existing systems.

23 October 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
PHPatrick He
Patrick He
CWChun Yuen Jerry Wong
Chun Yuen Jerry Wong
NLNicole Leung
Nicole Leung
GLGenevieve Long
Genevieve Long
MWMaria Wilson
Maria Wilson
DTDaniela Traini
Daniela Traini
Intranasal dry powder delivery offers a non-invasive route for rapid systemic drug absorption and may be particularly beneficial for antiemetic therapy when oral administration is compromised. However, conventional in vitro tools typically assess aerosol deposition or epithelial permeability in isolation, limiting their ability to discriminate formulation-dependent transport behaviour. Two spray-dried formulations, differing only in the presence or absence of a non-ionic surfactant, were characterised for physicochemical properties and aerosol performance, followed by biological evaluation using an air liquid interface (ALI) RPMI-2650 nasal epithelial model. Aerosol delivery was performed using a nasal powder device coupled to a modified expansion chamber and cascade impactor, enabling direct deposition onto epithelial cell layers. Cytocompatibility, epithelial barrier integrity, and transepithelial drug transport were assessed alongside quantitative mass balance. Both formulations exhibited comparable solid-state properties, high emitted-dose reproducibility, and similar regional nasal deposition profiles. Neither formulation induced cytotoxicity nor disrupted epithelial barrier integrity, as evidenced by unchanged transepithelial electrical resistance and paracellular permeability. Despite similar deposition behaviour, the surfactant-containing formulation demonstrated faster initial transport and consistently higher transepithelial transport trends, without evidence of barrier compromise. These differences are consistent with formulation-dependent processes following deposition, such as differences in surface wetting and dissolution behaviour at the air-liquid interface. Overall, this study demonstrates that aerosol deposition alone may not fully predict epithelial transport for intranasal dry powders. The integrated deposition-transport platform provides a robust in vitro tool for formulation screening and optimisation, supporting the development of intranasal antiemetic therapies and other nasal drug products requiring rapid and reliable systemic delivery.